Send us a Text Message.

In this week’s episode of On The Pen Live, guest Scott Liberto of PlanetScott.com joins to discuss his experience in the Survodutide clinical trial.

Survodutide is an investigational dual agonist targeting both the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. This novel drug is designed to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Support the Show.

MY WORK RELIES ON YOUR GENEROSITY, BECOME A MEMBER HERE:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER HERE:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

SOCIAL LINKS
https://www.tiktok.com/@manonthemounjaro
https://twitter.com/ManOnMounjaro
https://instagram.com/manonthemounjaro
https://facebook.com/manonthemounjaro

#Zepbound #releasethevials #mounjaro

📲 Contact Me: MounjaroMan@gmail.com

📼 PLAYLISTS:
🖊️ ON THE PEN LIVES:
https://www.youtube.com/playlist?list=PLtOcNl0C8quVdrWruYSrJpTZPF7jjXKfM
👀 WATCH MY MOUNJARO JOURNEY IN ORDER:
https://www.youtube.com/watch?v=aplFxNOv77g&list=PLtOcNl0C8quWo7PWY9j_HilhWIRuedyiO
😎 NERDS ONLY: LEARN ABOUT OTHER GLP-1 MEDS:
https://www.youtube.com/playlist?list=PLtOcNl0C8quW-YZuu_DSpt_NS9fVQbMoW
🚨📰 ALL THE LATEST MOUNJARO NEWS:
https://www.youtube.com/playlist?list=PLtOcNl0C8quVo0I2YODK-q7cHh4y1r2yB

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com.